Imatinib mesylate in the treatment of chronic myeloid leukaemia

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 6, 2003, Pages 963-971

  Druker, Brian J ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Bcr abl; Chronic myeloid leukemia; Imatinib mesylate; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYCLOSPORIN A; CYTARABINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; PHENYTOIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SIMVASTATIN;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANXIETY DISORDER; APLASIA; ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FOOD DRUG INTERACTION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INSOMNIA; LARYNX DISORDER; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PHARYNX DISEASE; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; RIGOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0038009044     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.6.963     Document Type: Review

References (58)

1. SAWYERS CL: Chronic myeloid leukemia. N. Engl. J. Med. (1999) 340:1330-1340.
2. FADERL S, TALPAZ M, ESTROV Z, KANTARJIAN HM: Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. (1999) 131:207-219.
3. NOWELL PC, HUNGERFORD DA: A minute chromosome in human chronic granulocytic leukemia. Science (1960) 132:1497-1501.
4. ROWLEY JD: A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature (1973) 243:290-293.
5. DE KLEIN A, GEURTS VAN KESSEL A, GROSVELD G et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature (1982) 200:765.
6. SHTIVELMAN E, LIFSHITZ B, GALE RP, CANAANI E: Fused transcript of Abl and Bcr genes in chronic myclogenous leukaemia. Nature (1985) 315:550-554.
7. BEN-NERIAH Y, DALEY GQ, MES-MASSON A-M, WITTE ON, BALTIMORE D: The chronic myelogenous leukemia-specific P210 protein is the product of the Bcr/Abl hybrid gene. Science (1986) 233:212-214.
8. HERMANS A, HEISTERKAMP N, VON LINDERN M et al.: Unique fusion of Bcr and c-Abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell (1987) 51:33-40.
9. CLARK SS, MCLAUGHLIN J, TIMMONS M et al.: Expression of a distinctive Bcr-abl oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science (1988) 239:775-777.
10. CHAN LC, KARHI KK, RAYTER SI et al.: A novel Abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature (1987) 325:635-637.
11. DALEY GQ, VAN ETTEN RA, BALTIMORE D: Induction of chronic myelogenous leukemia in mice by the P210Bcr/Abl gene of the Philadelphia chromosome. Science (1990) 247:824-830.
12. HEISTERKAMP N, JENSTER G, TEN HOEVE J, ZOVICH D, PATTENGALE PK, GROFFEN J: Acute leukaemia in Bcr/Abl transgenic mice. Nature (1990) 344:251-253.
13. KELLIHER MA, MCLAUGHLIN J, WITTE ON, ROSENBERG N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-Abl and Bcr/Abl. Proc. Natl. Acad. Sci. USA (1990) 87:6649-6653.
14. HUETTNER CS, ZHANG P, VAN ETTEN RA, TENEN DG: Reversibility of acute B-cell leukaemia induced by Bcr-abl1. Nat. Genet. (2000) 24:57-60.
15. LUGO TG, PENDERGAST AM, MULLER AJ, WITTE ON: Tyrosine kinase activity and transformation potency of Bcr-abl oncogene products. Science (1990) 247:1079-1082.
16. BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA (1995) 92:2558-2562.
17. BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56:100-104.
18. DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-abl positive cells. Nat. Med. (1996) 2:561-566.
19. DEININGER MW, GOLDMAN JM, LYDON N, MELO JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of Bcr-abl-positive cells. Blood (1997) 90:3691-3698.
20. + leukemic cells and induces apoptosis. Blood Cells Mol. Dis. (1997) 23:380-394.
21. DRUKER BJ, LYDON NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. (2000) 105:3-7.
22. RECKMANN AH, FISCHER T, PENG B et al.: Effect of food on STI571 (Glivec) pharmacokinetics and bioavailability. Proc. Am. Soc. Clin. Oncol. (2001) 20:1223a.
23. PENG B, HAYES M, RACINE-POON A et al.: Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc. Am. Soc. Clin. Oncol. (2001) 20:280a.
24. DRUKER BJ, TALPAZ M, RESTA D et al.: Efficacy and safety of a specific inhibitor of the Bcr-abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
25. O'BRIEN SG, PENG B, DUTREIX C et al.: A pharmacokinetic interaction of glivec and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia. Blood (2001) 98:141a.
26. ODA T, HEANEY C, HAGOPIAN J, OKUDA K, GRIFFIN JD, DRUKER BJ: CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. (1994) 269:22925-22928.
27. + leukemia. Blood (1994) 84:1731-1736.
28. NICHOLS GL, RAINES MA, VERA JC, LACOMIS L, TEMPST P, GOLDE DW: Identification of Crkl as the constitutively phosphorylated 39-kDa tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood (1994) 84:2912-2918.
29. FELLER SM: Crk family adaptors-signalling complex formation and biological roles. Oncogene (2001) 20:6348-6371.
30. HEANEY C, KOLIBABA K, BHAT A et al.: Direct binding of Crkl to Bcr-abl is not required for Bcr-abl transformation. Blood (1997) 89:297-306.
31. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by Bcr-abl gene mutation or amplification. Science (2001) 293:876-880.
32. HOCHHAUS A, KREIL S, CORBIN AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 16:2190-2196.
33. SHAH NP, NICOLL JM, NAGAR B et al.: Multiple Bcr-abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2:117-125.
34. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the Bcr-abl tyrosine kinase in the blast crisis of chronic myeloid. leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
35. KANTARJIAN H, SAWYERS C, HOCHHAUS A et al.: Haematological and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. (2002) 346:645-652.
36. TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable haematological and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99:1928-1937.
37. SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces haematological and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99:3530-3539.
38. OTTMANN OG, DRUKER BJ, SAWYERS CL et al.: A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 100:1965-1971.
39. O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) (In Press).
40. HUGHES T, KAEDA J, BRANFORD S et al.: Molecular responses to imatinib (STI571) or interferon plus Ara-C as initial therapy for CML: results in the IRIS study. Blood (2002) 100:93a.
41. DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347:472-480.
42. MAURO MJ, KURILIK G, BALLEISEN S, O'DWYER ME, FERNANDES-REESE S, DRUKER BJ: Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Blood (2001) 98:139a.
43. MARIN D, MARKTEL S, FOOT N, BUA M, GOLDMAN JM, APPERLEY JF: Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica (2003) 88:227-229.
44. CORTES JE, TALPAZ M, O'BRIEN S et al.: High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia in early chronic phase treated with imatinib at 400 mg or 800 mg daily. Blood (2002) 100:95a.
45. O'DWYER ME, MAURO MJ, KUYL J, PAQUETTE R, SAWYERS CL, DRUKER BJ: Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-α for the treatment of chronic phase CML. Blood (2001) 98:846a.
46. O'BRIEN SG, VALLANCE SE, CRADDOCK C, HOLYOAKE TL, GOLDMAN JM, The UK PISCES Group: PEG-Intron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood (2001) 98:846a.
47. 2a (Pegasys) Phase I/II combination study in chronic phase chronic myelogenous; leukemia. Blood (2002) 100:164a.
48. DRUKER B, KANTARJIAN H, TALPAZ M et al.: A Phase I study of the combination of gleevec (imatinib mesylate) with low dose Ara-C. Blood (2001) 98:845a.
49. GARDEMBAS M, ROUSSELOT P, TULLIEZ M et al.: Imatinib (Gleevec) and cytarabine (Ara-C) is an effective regimen in Philadelphia (Ph)-positive chronic myelogenous leukemia (CML) chronic phase patients. Blood (2002) 100:95a.
50. CORBIN AS, LA ROSÉE P, STOFFREGEN E, DRUKER BJ, DEININGER MW: Several Bcr-abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) (In Press).
51. GAMBACORTI-PASSERINI CB, GUNBY RH, PIAZZA R, GALIETTA. A, ROSTAGNO R, SCAPOZZA L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncol. 4:75-85.
52. GRAHAM SM, JORGENSEN HG, ALLAN E et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 99:319-325.
53. HOLTZ MS, SLOVAK ML, ZHANG F, SAWYERS CL, FORMAN SJ, BHATIA R: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood (2002) 99:3792-3800.
54. VAN OOSTEROM AT, JUDSON I, VERWEIJ J et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421-1423.
55. APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor-β. N. Engl. J. Med. (2002) 347:481-487.
56. MAGNUSSON MK, MEADE KE, NAKAMURA R, BARRETT J, DUNBAR CE: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor-β receptor fusion oncogene. Blood (2002) 100:1088-1091.
57. RUBIN BP, SCHUETZE SM, EARY JF et al.: Molecular targeting of platelet-derived growth factor-β by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. (2002) 20:3568-3569.
58. COOL J, DE ANGELO DJ, GOTLIB et al.: A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348:1201-1214.